Literature DB >> 24339250

Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor.

Sankar Mohan1, Philip S Kerry, Nicole Bance, Masahiro Niikura, B Mario Pinto.   

Abstract

We have previously reported a potent neuraminidase inhibitor that comprises a carbocyclic analogue of zanamivir in which the hydrophilic glycerol side chain is replaced by the hydrophobic 3-pentyloxy group of oseltamivir. This hybrid inhibitor showed excellent inhibitory properties in the neuraminidase inhibition assay (Ki =0.46 nM; Ki (zanamivir) =0.16 nM) and in the viral replication inhibition assay in cell culture at 10(-8)  M. As part of this lead optimization, we now report a novel spirolactam that shows comparable inhibitory activity in the cell culture assay to that of our lead compound at 10(-7)  M. The compound was discovered serendipitously during the attempted synthesis of the isothiourea derivative of the original candidate. The X-ray crystal structure of the spirolactam in complex with the N8 subtype neuraminidase offers insight into the mode of inhibition.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antiviral agents; drug discovery; influenza A; neuraminidase inhibitors; spiro compounds

Mesh:

Substances:

Year:  2013        PMID: 24339250     DOI: 10.1002/anie.201308142

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  7 in total

1.  Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.

Authors:  Wenwen Lian; Jiansong Fang; Chao Li; Xiaocong Pang; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2015-12-21       Impact factor: 2.943

2.  Factor H-Inspired Design of Peptide Biomarkers of the Complement C3d Protein.

Authors:  Reed E S Harrison; Nehemiah T Zewde; Yogesh B Narkhede; Rohaine V Hsu; Dimitrios Morikis; Valentine I Vullev; Giulia Palermo
Journal:  ACS Med Chem Lett       Date:  2020-02-28       Impact factor: 4.345

Review 3.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

4.  Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases.

Authors:  Anja Hoffmann; Martina Richter; Susanne von Grafenstein; Elisabeth Walther; Zhongli Xu; Lilia Schumann; Ulrike Grienke; Christina E Mair; Christian Kramer; Judith M Rollinger; Klaus R Liedl; Michaela Schmidtke; Johannes Kirchmair
Journal:  Front Microbiol       Date:  2017-02-15       Impact factor: 5.640

5.  Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.

Authors:  Jennifer L McKimm-Breschkin; Alicia M Fry
Journal:  Antiviral Res       Date:  2016-02-09       Impact factor: 5.970

6.  Catalytic Enantioselective Entry to Triflones Featuring a Quaternary Stereocenter.

Authors:  Francesca Franco; Sara Meninno; Jacob Overgaard; Sergio Rossi; Maurizio Benaglia; Alessandra Lattanzi
Journal:  Org Lett       Date:  2022-06-10       Impact factor: 6.072

Review 7.  A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action.

Authors:  Jie Yang; Shuwen Liu; Lanying Du; Shibo Jiang
Journal:  Rev Med Virol       Date:  2016-04-08       Impact factor: 6.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.